Pharmaceuticals in South Korea

Date: June 30, 2017
Pages: 38
Price:
US$ 350.00 US$ 315.00
Offer valid until September 1, 2017!
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PAE59D33030EN
Leaflet:

Download PDF Leaflet

Pharmaceuticals in South Korea
Pharmaceuticals in South Korea

SUMMARY

Pharmaceuticals in South Korea industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

SYNOPSIS

Essential resource for top-line data and analysis covering the South Korea pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

KEY HIGHLIGHTS
  • The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2016 annual average exchange rates.
  • The South Korean pharmaceuticals market had total revenues of $18.0bn in 2016, representing a compound annual growth rate (CAGR) of 1.6% between 2012 and 2016.
  • Plans to introduce full medical coverage for four major chronic disease areas - cancer, cardiovascular, cerebrovascular and rare diseases - as part of expansion of National Health Insurance (NHI) coverage, is expected to drive growth in the next five years.
  • The South Korean government has been providing help to companies such as Celltrion and Samsung build a presence in biosimilar drugs. Biosimilar drugs are said to be almost impossible to replicate exactly – unlike traditional drugs which can be easily copied once patents expire – and is an area undergoing growth.
SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in South Korea
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in South Korea
  • Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the South Korea pharmaceuticals market with five year forecasts
REASONS TO BUY
  • What was the size of the South Korea pharmaceuticals market by value in 2016?
  • What will be the size of the South Korea pharmaceuticals market in 2021?
  • What factors are affecting the strength of competition in the South Korea pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitiors in South Korea's pharmaceuticals market?
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
CKD Bio Corporation
Daewoong Pharmaceutical Co., Ltd.
Hanmi Science Co., Ltd.
Pfizer Inc.
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: South Korea pharmaceuticals market value: $ billion, 2012–16
Table 2: South Korea pharmaceuticals market geography segmentation: $ billion, 2016
Table 3: South Korea pharmaceuticals market share: % share, by value, 2016
Table 4: South Korea pharmaceuticals market value forecast: $ billion, 2016–21
Table 5: CKD Bio Corporation: key facts
Table 6: Daewoong Pharmaceutical Co., Ltd.: key facts
Table 7: Daewoong Pharmaceutical Co., Ltd.: key financials ($)
Table 8: Daewoong Pharmaceutical Co., Ltd.: key financials (KRW)
Table 9: Daewoong Pharmaceutical Co., Ltd.: key financial ratios
Table 10: Hanmi Science Co., Ltd.: key facts
Table 11: Hanmi Science Co., Ltd.: key financials ($)
Table 12: Hanmi Science Co., Ltd.: key financials (KRW)
Table 13: Hanmi Science Co., Ltd.: key financial ratios
Table 14: Pfizer Inc.: key facts
Table 15: Pfizer Inc.: key financials ($)
Table 16: Pfizer Inc.: key financial ratios
Table 17: South Korea size of population (million), 2012–16
Table 18: South Korea gdp (constant 2005 prices, $ billion), 2012–16
Table 19: South Korea gdp (current prices, $ billion), 2012–16
Table 20: South Korea inflation, 2012–16
Table 21: South Korea consumer price index (absolute), 2012–16
Table 22: South Korea exchange rate, 2012–16

LIST OF FIGURES

Figure 1: South Korea pharmaceuticals market value: $ billion, 2012–16
Figure 2: South Korea pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 3: South Korea pharmaceuticals market share: % share, by value, 2016
Figure 4: South Korea pharmaceuticals market value forecast: $ billion, 2016–21
Figure 5: Forces driving competition in the pharmaceuticals market in South Korea, 2016
Figure 6: Drivers of buyer power in the pharmaceuticals market in South Korea, 2016
Figure 7: Drivers of supplier power in the pharmaceuticals market in South Korea, 2016
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in South Korea, 2016
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in South Korea, 2016
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in South Korea, 2016
Figure 11: Daewoong Pharmaceutical Co., Ltd.: revenues & profitability
Figure 12: Daewoong Pharmaceutical Co., Ltd.: assets & liabilities
Figure 13: Hanmi Science Co., Ltd.: revenues & profitability
Figure 14: Hanmi Science Co., Ltd.: assets & liabilities
Figure 15: Pfizer Inc.: revenues & profitability
Figure 16: Pfizer Inc.: assets & liabilities

COMPANIES MENTIONED

CKD Bio Corporation
Daewoong Pharmaceutical Co., Ltd.
Hanmi Science Co., Ltd.
Pfizer Inc.
Skip to top


OTC Pharmaceuticals in South Korea US$ 315.00 Sep, 2016 · 35 pages

Ask Your Question

Pharmaceuticals in South Korea
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: